View Filing Data

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Jun. 30, 2011	Aug. 01, 2011
Document And Entity Information
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2011
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2011
Entity Registrant Name	ARROWHEAD RESEARCH CORP
Entity Central Index Key	0000879407
Current Fiscal Year End Date	--09-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		71,833,693

Consolidated Balance Sheets - USD ($)	Jun. 30, 2011	Sep. 30, 2010
CURRENT ASSETS
Cash and cash equivalents	$ 4,316,308	$ 6,847,162
Trade receivable, net of allowance for doubtful accounts of $90,789 at September 30, 2010		58,864
Other receivables	1,349,898	871,819
Prepaid expenses and other current assets	204,642	353,930
Marketable securities	1,177,708
TOTAL CURRENT ASSETS	7,048,556	8,131,775
PROPERTY AND EQUIPMENT
Computers, office equipment and furniture	285,266	335,784
Research equipment	3,515	752,850
Software	77,020	150,445
Leasehold improvements		78,594
Property, Plant and Equipment, Gross, Total	365,801	1,317,673
Less: Accumulated depreciation and amortization	(335,880)	(1,176,404)
PROPERTY AND EQUIPMENT, NET	29,921	141,269
OTHER ASSETS
Rent deposit		34,735
Patents	1,791,662	2,046,836
Note Receivable, net	2,231,509
Derivative asset	284,625
Investment in Nanotope Inc., equity basis	1,716,561	1,812,927
Investment in Leonardo Biosystems Inc., at cost	187,000	187,000
TOTAL OTHER ASSETS	6,211,357	4,081,498
TOTAL ASSETS	13,289,834	12,354,542
CURRENT LIABILITIES
Accounts payable	501,278	681,563
Accrued expenses	472,279	494,736
Accrued payroll and benefits	227,696	191,425
Derivative liabilities	958,451	2,408,522
Note payable		500,000
TOTAL CURRENT LIABILITIES	2,159,704	4,276,246
LONG-TERM LIABILITIES
Note payable	560,878
TOTAL LONG-TERM LIABILITIES	560,878
Commitments and contingencies
STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 145,000,000 shares authorized; 71,833,693 and 71,720,137 shares issued and outstanding as of June 30, 2011 and September 30, 2010, respectively	71,849	71,735
Additional paid-in capital	121,649,155	119,716,834
Accumulated deficit during the development stage	(111,095,229)	(110,742,867)
Total Arrowhead Research Corporation stockholders' equity	10,625,775	9,045,702
Noncontrolling interest	(56,523)	(967,406)
TOTAL STOCKHOLDERS' EQUITY	10,569,252	8,078,296
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 13,289,834	$ 12,354,542

Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2011	Sep. 30, 2010
Consolidated Balance Sheets
Trade receivable, allowance for doubtful accounts		$ 90,789
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	145,000,000	145,000,000
Common stock, shares issued	71,833,693	71,720,137
Common stock, shares outstanding	71,833,693	71,720,137

Consolidated Statements Of Operations - USD ($)	3 Months Ended		9 Months Ended		98 Months Ended
Consolidated Statements Of Operations - USD ($)	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011
Consolidated Statements Of Operations
REVENUE			$ 296,139		$ 3,991,959
OPERATING EXPENSES
Salaries	$ 354,223	$ 81,096	1,087,714	$ 802,122	19,656,556
General and administrative expenses	643,165	736,443	2,097,538	1,796,326	23,866,803
Research and development	365,618	123,343	2,768,130	372,554	39,919,100
Stock-based compensation	346,707	390,227	1,078,951		12,042,095
Patent amortization	60,452	60,452	181,356	181,356	1,721,492
TOTAL OPERATING EXPENSES	1,770,165	1,391,561	7,213,689	4,047,755	97,206,046
OPERATING LOSS	(1,770,165)	(1,391,561)	(6,917,550)	(4,047,755)	(93,214,087)
OTHER INCOME (EXPENSE)
Loss on equity of investments - Nanotope	(70,366)	(66,489)	(96,367)	(165,727)	(656,440)
Gain on sale of stock in subsidiary					2,292,800
Loss on sale of fixed assets, net					(127,088)
Realized and unrealized gain (loss) on marketable securities	(498,406)		(138,486)		243,778
Interest income (expense), net	20,531	(9,814)	70,815	(28,280)	2,698,764
Change in value of derivatives	373,734	1,552,228	1,243,156	1,552,228	3,004,541
TOTAL OTHER INCOME (EXPENSE)	(174,507)	1,475,925	1,079,118	1,358,221	7,456,355
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(1,944,672)	84,364	(5,838,432)	(2,689,534)	(85,757,732)
Provision for income taxes
LOSS FROM CONTINUING OPERATIONS	(1,944,672)	84,364	(5,838,432)	(2,689,534)	(85,757,732)
Income (loss) from discontinued operations	(68,742)	(768,160)	1,373,758	(2,383,288)	(47,546,200)
Gain (loss) on disposal of discontinued operations			3,919,213	430,000	4,708,588
NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS	(68,742)	(768,160)	5,292,971	(1,953,288)	(42,837,612)
NET INCOME (LOSS)	(2,013,414)	(683,796)	(545,461)	(4,642,822)	(128,595,344)
Net (income) loss attributable to noncontrolling interests	193,497	312,741	193,099	872,880	17,664,075
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD	$ (1,819,917)	$ (371,055)	$ (352,362)	$ (3,769,942)	$ (110,931,269)
Earnings per share - basic:
Income (loss) from continuing operations attributable to Arrowhead common shareholders	$ (0.03)		$ (0.07)	$ (0.03)
Income from discontinued operations attributable to Arrowhead common shareholders		$ (0.01)	$ 0.07	(0.03)
Net income (loss) attributable to Arrowhead shareholders	$ (0.03)	$ (0.01)		$ (0.06)
Weighted average shares outstanding	71,826,276	64,579,403	71,804,027	62,056,412
Earnings per share - diluted:
Income (loss) from continuing operations attributable to Arrowhead common shareholders	$ (0.03)		$ (0.07)	$ (0.03)
Income from discontinued operations attributable to Arrowhead common shareholders		$ (0.01)	$ 0.07	(0.03)
Net income (loss) attributable to Arrowhead shareholders	$ (0.03)	$ (0.01)		$ (0.06)
Weighted average shares outstanding	71,826,276	64,579,403	78,567,954	62,056,412

Consolidated Statement Of Stockholders' Equity - USD ($)	Issued For Cash @ $1.00 Per Unit [Member] Common Stock [Member]	Issued For Cash @ $1.00 Per Unit [Member] Additional Paid-In Capital [Member]	Issued For Cash @ $1.00 Per Unit [Member]	Issued For Marketable Securities @ $1.00 Per Unit [Member] Common Stock [Member]	Issued For Marketable Securities @ $1.00 Per Unit [Member] Additional Paid-In Capital [Member]	Issued For Marketable Securities @ $1.00 Per Unit [Member]	Issued For Cash @ $1.50 Per Unit [Member] Common Stock [Member]	Issued For Cash @ $1.50 Per Unit [Member] Additional Paid-In Capital [Member]	Issued For Cash @ $1.50 Per Unit [Member]	Stock Issuance Cost Charged To Additional Paid In Capital [Member] Additional Paid-In Capital [Member]	Stock Issuance Cost Charged To Additional Paid In Capital [Member]	Arrowheads Increase In Proportionate Share Of Insert Therapeutics Equity [Member] Additional Paid-In Capital [Member]	Arrowheads Increase In Proportionate Share Of Insert Therapeutics Equity [Member]	Arrowheads Increase In Proportionate Share Of Calando's Equity [Member] Additional Paid-In Capital [Member]	Arrowheads Increase In Proportionate Share Of Calando's Equity [Member]	Issued As A Gift For $1.09 Per Share [Member] Common Stock [Member]	Issued As A Gift For $1.09 Per Share [Member] Additional Paid-In Capital [Member]	Issued As A Gift For $1.09 Per Share [Member]	Issued As Stock Issuance Cost @ $1.50 Per Unit [Member] Common Stock [Member]	Issued As Stock Issuance Cost @ $1.50 Per Unit [Member] Additional Paid-In Capital [Member]	Issued As Stock Issuance Cost @ $1.50 Per Unit [Member]	Exercised @ $0.20 Per Share [Member] Common Stock [Member]	Exercised @ $0.20 Per Share [Member] Additional Paid-In Capital [Member]	Exercised @ $0.20 Per Share [Member]	Exercised @ $1.00 Per Share [Member] Common Stock [Member]	Exercised @ $1.00 Per Share [Member] Additional Paid-In Capital [Member]	Exercised @ $1.00 Per Share [Member]	Issued To Purchase Insert Therapeutics Share @ $3.98 Per Share [Member] Common Stock [Member]	Issued To Purchase Insert Therapeutics Share @ $3.98 Per Share [Member] Additional Paid-In Capital [Member]	Issued To Purchase Insert Therapeutics Share @ $3.98 Per Share [Member]	Issued @ $4.88 Per Share [Member] Common Stock [Member]	Issued @ $4.88 Per Share [Member] Additional Paid-In Capital [Member]	Issued @ $4.88 Per Share [Member]	Issued @ $3.84 Per Share [Member] Common Stock [Member]	Issued @ $3.84 Per Share [Member] Additional Paid-In Capital [Member]	Issued @ $3.84 Per Share [Member]	Issued @ $3.50 Per Share [Member] Common Stock [Member]	Issued @ $3.50 Per Share [Member] Additional Paid-In Capital [Member]	Issued @ $3.50 Per Share [Member]	Issued @ $5.91 Per Share [Member] Common Stock [Member]	Issued @ $5.91 Per Share [Member] Additional Paid-In Capital [Member]	Issued @ $5.91 Per Share [Member]	Issued To Purchase Calando Pharmaceuticals, Inc. @ $5.17 Per Share [Member] Common Stock [Member]	Issued To Purchase Calando Pharmaceuticals, Inc. @ $5.17 Per Share [Member] Additional Paid-In Capital [Member]	Issued To Purchase Calando Pharmaceuticals, Inc. @ $5.17 Per Share [Member]	Issued @ $5.78 Per Share, Net [Member] Common Stock [Member]	Issued @ $5.78 Per Share, Net [Member] Additional Paid-In Capital [Member]	Issued @ $5.78 Per Share, Net [Member]	Issued For Purchase Of Carbon Nanotechnologies, Inc. @ $3.77 Per Share [Member] Common Stock [Member]	Issued For Purchase Of Carbon Nanotechnologies, Inc. @ $3.77 Per Share [Member] Additional Paid-In Capital [Member]	Issued For Purchase Of Carbon Nanotechnologies, Inc. @ $3.77 Per Share [Member]	Issued At Approximately $1.80 Per Share, Net [Member] Common Stock [Member]	Issued At Approximately $1.80 Per Share, Net [Member] Additional Paid-In Capital [Member]	Issued At Approximately $1.80 Per Share, Net [Member]	Issued @ $2.72 Per Share To Rice University [Member] Common Stock [Member]	Issued @ $2.72 Per Share To Rice University [Member] Additional Paid-In Capital [Member]	Issued @ $2.72 Per Share To Rice University [Member]	Issued @ $2.83 Per Share To Purchase Shares Of Unidym, Inc. [Member] Common Stock [Member]	Issued @ $2.83 Per Share To Purchase Shares Of Unidym, Inc. [Member] Additional Paid-In Capital [Member]	Issued @ $2.83 Per Share To Purchase Shares Of Unidym, Inc. [Member]	Issued @ $2.95 Per Share To Purchase MASA Energy, LLC [Member] Common Stock [Member]	Issued @ $2.95 Per Share To Purchase MASA Energy, LLC [Member] Additional Paid-In Capital [Member]	Issued @ $2.95 Per Share To Purchase MASA Energy, LLC [Member]	Issued @ $2.19 Per Share To Unidym For The Acquisition Of Nanoconduction [Member] Common Stock [Member]	Issued @ $2.19 Per Share To Unidym For The Acquisition Of Nanoconduction [Member] Additional Paid-In Capital [Member]	Issued @ $2.19 Per Share To Unidym For The Acquisition Of Nanoconduction [Member]	Issued @ $2.18 Per Share [Member] Common Stock [Member]	Issued @ $2.18 Per Share [Member] Additional Paid-In Capital [Member]	Issued @ $2.18 Per Share [Member]	Issued @ $0.55 Per Share To Unidym Stockholder In Exchange For Unidym's Shares [Member] Common Stock [Member]	Issued @ $0.55 Per Share To Unidym Stockholder In Exchange For Unidym's Shares [Member] Additional Paid-In Capital [Member]	Issued @ $0.55 Per Share To Unidym Stockholder In Exchange For Unidym's Shares [Member]	Issued @ $0.52 Per Share To TEL Ventures In Exchange For Unidym's Shares [Member] Common Stock [Member]	Issued @ $0.52 Per Share To TEL Ventures In Exchange For Unidym's Shares [Member] Additional Paid-In Capital [Member]	Issued @ $0.52 Per Share To TEL Ventures In Exchange For Unidym's Shares [Member]	Issued @ $0.30 Per Share [Member] Common Stock [Member]	Issued @ $0.30 Per Share [Member] Additional Paid-In Capital [Member]	Issued @ $0.30 Per Share [Member]	Series D Preferred Stock Issued For Subscription In Unidym [Member] Subscription Receivable [Member]	Series D Preferred Stock Issued For Subscription In Unidym [Member] Additional Paid-In Capital [Member]	Issued @ $0.63 Per Share [Member] Common Stock [Member]	Issued @ $0.63 Per Share [Member] Additional Paid-In Capital [Member]	Issued @ $0.63 Per Share [Member]	Issued @ $1.312 Per Share [Member] Common Stock [Member]	Issued @ $1.312 Per Share [Member] Additional Paid-In Capital [Member]	Issued @ $1.312 Per Share [Member]	Issued To Unidym Stockholders In Exchange For Unidym's Shares [Member] Common Stock [Member]	Issued To Unidym Stockholders In Exchange For Unidym's Shares [Member] Additional Paid-In Capital [Member]	Issued To Unidym Stockholders In Exchange For Unidym's Shares [Member] Noncontrolling Interest [Member]	Issued To Calando Stockholders In Exchange For Calando's Shares [Member] Common Stock [Member]	Issued To Calando Stockholders In Exchange For Calando's Shares [Member] Additional Paid-In Capital [Member]	Issued To Calando Stockholders In Exchange For Calando's Shares [Member] Noncontrolling Interest [Member]	Subscription Receivable [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Stock issued during period, value, new issues	$ 475	$ 474,525	$ 475,000	$ 500	$ 499,500	$ 500,000	$ 6,609	$ 9,906,573	$ 9,913,182							$ 163	$ 162,587	$ 162,750	$ 356	$ 533,988	$ 534,344																																																																									$ 706	$ (151,175)			$ (150,469)
Stock issued during period, shares, new issues	475,000			500,000			6,608,788									150,000			356,229																																																																											705,529
Stock issuance cost charged to additional paid-in capital										$ (96,500)	$ (96,500)																																																																																				(991,318)			(991,318)
Net loss attributable to Arrowhead																																																																																																(2,528,954)	1,777,699	(751,255)
Stock issued during period, value, stock options exercised																						$ 75	$ 14,925	$ 15,000	$ 6	$ 5,994	$ 6,000																																																																			$ 75	14,925			15,000
Stock issued during period, shares, stock options exercised																						75,000			6,000																																																																					75,000
Adjustments to additional paid in capital, share-based compensation, requisite service period recognition, value																																																																																															175,653			175,653
Stockholders' equity, including portion attributable to noncontrolling interest, ending balance at Sep. 30, 2004																																																																																														$ 13,645	12,059,997	(2,624,192)	1,777,699	11,227,149
Shares, issued at Sep. 30, 2004																																																																																														13,631,546
Stock issued during period, value, new issues							$ 13,813	$ 20,705,522	$ 20,719,335																$ 25	$ 24,975	$ 25,000	$ 502	$ 1,999,498	$ 2,000,000																																																																$ 12	49,988			50,000
Stock issued during period, shares, new issues							13,812,888																		25,000			502,260																																																																		12,500
Net loss attributable to Arrowhead																																																																																																(6,854,918)	121,491	(6,733,427)
Adjustments to additional paid in capital, share-based compensation, requisite service period recognition, value																																																																																															508,513			508,513
Adjustments to additional paid in capital, reallocation of noncontrolling interest																																																																																															230,087			230,087
Stockholders' equity, including portion attributable to noncontrolling interest, ending balance at Sep. 30, 2005																																																																																														$ 27,997	35,578,580	(9,479,110)	1,899,190	28,026,657
Shares, issued at Sep. 30, 2005																																																																																														27,984,194
Stock issued during period, value, new issues																															$ 205	$ 999,795	$ 1,000,000	$ 15	$ 57,585	$ 57,600	$ 5,590	$ 19,539,410	$ 19,545,000	$ 25	$ 149,975	$ 150,000	$ 208	$ 1,077,125	$ 1,077,333
Stock issued during period, shares, new issues																															204,854			15,000			5,590,000			25,364			208,382
Net loss attributable to Arrowhead																																																																																																(18,997,209)	(964,752)	(19,961,961)
Stock issued during period, value, stock options exercised																																																																																														$ 116	341,421			341,537
Stock issued during period, shares, stock options exercised																																																																																														115,794
Adjustments to additional paid in capital, share-based compensation, requisite service period recognition, value																																																																																															1,369,478			1,369,478
Stockholders' equity, including portion attributable to noncontrolling interest, ending balance at Sep. 30, 2006																																																																																														$ 34,156	59,113,369	(28,476,319)	934,438	31,605,644
Shares, issued at Sep. 30, 2006																																																																																														34,143,588
Stock issued during period, value, new issues																																														$ 2,849	$ 15,149,366	$ 15,152,215	$ 1,431	$ 5,398,569	$ 5,400,000
Stock issued during period, shares, new issues																																														2,849,446			1,431,222
Net loss attributable to Arrowhead																																																																																																(29,931,118)	(781,829)	(30,712,947)
Stock issued during period, value, stock options exercised																																																																																														$ 186	434,541			434,727
Stock issued during period, shares, stock options exercised																																																																																														186,164
Adjustments to additional paid in capital, share-based compensation, requisite service period recognition, value																																																																																															2,175,544			2,175,544
Adjustments to additional paid in capital, reallocation of noncontrolling interest												$ 2,401,394	$ 2,401,394
Stockholders' equity, including portion attributable to noncontrolling interest, ending balance at Sep. 30, 2007																																																																																														$ 38,622	84,672,783	(58,407,437)	152,609	26,456,577
Shares, issued at Sep. 30, 2007																																																																																														38,610,420
Stock issued during period, value, new issues																																																				$ 3,867	$ 6,956,718	$ 6,960,585	$ 50	$ 135,950	$ 136,000	$ 71	$ 199,929	$ 200,000	$ 105	$ 309,895	$ 310,000	$ 114	$ 249,886	$ 250,000	$ 15	$ 32,685	$ 32,700
Stock issued during period, shares, new issues																																																				3,863,989			50,000			70,547			105,049			114,155			15,000
Net loss attributable to Arrowhead																																																																																																(27,089,030)	(152,609)	(27,241,639)
Stock issued during period, value, stock options exercised																																																																																														$ 106	289,921			290,027
Stock issued during period, shares, stock options exercised																																																																																														105,357
Adjustments to additional paid in capital, share-based compensation, requisite service period recognition, value																																																																																															3,187,397			3,187,397
Adjustments to additional paid in capital, reallocation of noncontrolling interest																																																																																															1,720,962			1,720,962
Stockholders' equity, including portion attributable to noncontrolling interest, ending balance at Sep. 30, 2008																																																																																														$ 42,950	97,756,126	(85,496,467)		12,302,609
Shares, issued at Sep. 30, 2008																																																																																														42,934,517
Stock issued during period, value, new issues																																																																						$ 2,059	$ 1,131,617	$ 1,133,676	$ 2,222	$ 1,156,111	$ 1,158,333	$ 9,197	$ 2,749,796	$ 2,758,993
Stock issued during period, shares, new issues																																																																						2,058,393			2,222,222			9,196,642
Reclassification of former Unidym mezzanine debt to equity																																																																																															2,000,000			2,000,000
Net loss attributable to Arrowhead																																																																																																(19,308,392)		(19,308,392)
Adjustments to additional paid in capital, share-based compensation, requisite service period recognition, value																																																																																															2,676,170			2,676,170
Adjustments to additional paid in capital, reallocation of noncontrolling interest														$ 2,120,250	$ 2,120,250																																																																																16,297			16,297
Issuance of preferred stock in subsidiary																																																																															$ (300,000)	$ 300,000
Amortization of discount on Unidym Series D Preferred Stock																																																																																															163,960	(163,960)
Stockholders' equity, including portion attributable to noncontrolling interest, ending balance at Sep. 30, 2009																																																																																													(300,000)	$ 56,428	110,070,327	(104,968,819)		4,857,936
Shares, issued at Sep. 30, 2009																																																																																														56,411,774
Stock issued during period, value, new issues																																																																																	$ 5,083	$ 3,217,813	$ 3,222,896	$ 6,593	$ 3,692,078	$ 3,698,671	$ 153	$ (1,435)	$ 1,282	$ 1,220	$ (160,667)	$ 159,447		$ 2,251	1,063,600		200	1,066,051
Stock issued during period, shares, new issues																																																																																	5,083,430			6,592,989			153,176			1,220,000				2,251,893
Net loss attributable to Arrowhead																																																																																																(5,774,048)	(1,182,990)	(6,957,038)
Stock issued during period, value, stock options exercised																																																																																														$ 7	7,624			7,631
Stock issued during period, shares, stock options exercised																																																																																														6,875
Adjustments to additional paid in capital, share-based compensation, requisite service period recognition, value																																																																																															1,582,149			1,582,149
Adjustments to additional paid in capital, reallocation of noncontrolling interest																																																																																															245,345		54,655	300,000
Issuance of preferred stock in subsidiary																																																																																													300,000					300,000
Stockholders' equity, including portion attributable to noncontrolling interest, ending balance at Sep. 30, 2010																																																																																														$ 71,735	119,716,834	(110,742,867)	(967,406)	8,078,296
Shares, issued at Sep. 30, 2010																																																																																														71,720,137
Stock issued during period, value, new issues																																																																																														$ 87	43,192			43,279
Stock issued during period, shares, new issues																																																																																														86,557
Net loss attributable to Arrowhead																																																																																																(352,362)	(193,099)	(352,362)
Stock issued during period, value, stock options exercised																																																																																														$ 27	13,857			13,884
Stock issued during period, shares, stock options exercised																																																																																														26,999
Adjustments to additional paid in capital, share-based compensation, requisite service period recognition, value																																																																																															1,106,470			1,106,470
Adjustments to additional paid in capital, reallocation of noncontrolling interest																																																																																															(849,707)		849,707
Issuance of preferred stock in subsidiary																																																																																															1,618,509			1,618,509
Stockholders' equity, including portion attributable to noncontrolling interest, ending balance at Jun. 30, 2011																																																																																														$ 71,849	121,649,155	(111,095,229)	(56,523)	10,569,252
Shares, issued at Jun. 30, 2011																																																																																														71,833,693
Divestiture of Unidym																																																																																																	$ 254,275	$ 254,275

Consolidated Statement Of Stockholders' Equity (Parenthetical) - $ / shares	Sep. 30, 2010	Sep. 30, 2009	Sep. 30, 2008	Sep. 30, 2007	Sep. 30, 2006	Sep. 30, 2005	Sep. 30, 2004	Sep. 30, 2003
Issued For Cash @ $0.001 Per Unit [Member]
Common stock & warrants issued for cash, price per unit								$ 0.001
Issued For Cash @ $1.00 Per Unit [Member]
Common stock & warrants issued for cash, price per unit							$ 1	$ 1
Issued For Marketable Securities @ $1.00 Per Unit [Member]
Common stock & warrants issued for cash, price per unit							1
Issued For Cash @ $1.50 Per Unit [Member]
Common stock & warrants issued for cash, price per unit							1.5
Issued As A Gift For $1.09 Per Share [Member]
Common stock & warrants issued for cash, price per unit							1.09
Issued As Stock Issuance Cost @ $1.50 Per Unit [Member]
Common stock & warrants issued for cash, price per unit							1.5
Exercised @ $0.20 Per Share [Member]
Exercise of stock options, price per share							0.2
Exercised @ $1.00 Per Share [Member]
Exercise of stock options, price per share						$ 1	$ 1
Exercised @ $1.50 Per Share [member]
Exercise of stock options, price per share						1.5
Issued To Purchase Insert Therapeutics Share @ $3.98 Per Share [Member]
Common stock issued, par value per share						$ 3.98
Issued @ $4.88 Per Share [Member]
Common stock issued, par value per share					$ 4.88
Issued @ $3.84 Per Share [Member]
Common stock issued, par value per share					3.84
Issued @ $3.50 Per Share [Member]
Common stock issued, par value per share					3.5
Issued @ $5.91 Per Share [Member]
Common stock issued, par value per share					5.91
Issued To Purchase Calando Pharmaceuticals, Inc. @ $5.17 Per Share [Member]
Common stock issued, par value per share					$ 5.17
Issued @ $5.78 Per Share, Net [Member]
Common stock issued, par value per share				$ 5.78
Issued For Purchase Of Carbon Nanotechnologies, Inc. @ $3.77 Per Share [Member]
Common stock issued, par value per share				$ 3.77
Issued At Approximately $1.80 Per Share, Net [Member]
Common stock issued, par value per share			$ 1.8
Issued @ $2.72 Per Share To Rice University [Member]
Common stock issued, par value per share			2.72
Issued @ $2.83 Per Share To Purchase Shares Of Unidym, Inc. [Member]
Common stock issued, par value per share			2.83
Issued @ $2.95 Per Share To Purchase MASA Energy, LLC [Member]
Common stock issued, par value per share			2.95
Issued @ $2.19 Per Share To Unidym For The Acquisition Of Nanoconduction [Member]
Common stock issued, par value per share			2.19
Issued @ $2.18 Per Share [Member]
Common stock issued, par value per share			$ 2.18
Issued @ $0.55 Per Share To Unidym Stockholder In Exchange For Unidym's Shares [Member]
Common stock issued, par value per share		$ 0.55
Issued @ $0.52 Per Share To TEL Ventures In Exchange For Unidym's Shares [Member]
Common stock issued, par value per share		0.52
Issued @ $0.30 Per Share [Member]
Common stock issued, par value per share		$ 0.3
Issued @ $0.63 Per Share [Member]
Common stock issued, par value per share	$ 0.63
Issued @ $1.312 Per Share [Member]
Common stock issued, par value per share	$ 1.312

Consolidated Statements Of Cash Flows - USD ($)	9 Months Ended		98 Months Ended
Consolidated Statements Of Cash Flows - USD ($)	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (545,461)	$ (4,642,822)	$ (128,595,344)
Net (income) loss attributable to noncontrolling interests	193,099	872,880	17,664,075
Net income (loss) attributable to Arrowhead	(352,362)	(3,769,942)	(110,931,269)
(Income) loss from discontinued operations	(5,292,971)	1,953,288	42,837,612
Realized and unrealized (gain) loss on investments	138,486		(943,777)
(Gain) loss from sale of subsidiary			(306,344)
Loss on sale/donation of fixed assets			127,088
Stock issued as gift			298,750
Stock issued for professional services			248,997
Stock issued for in-process research and development			13,166,347
Change in value of derivatives	(1,243,156)	(1,552,228)	(3,004,541)
Purchased in-process research and development - Nanoconduction			2,685,208
Stock-based compensation	1,078,951		12,042,095
Depreciation and amortization	203,041	209,450	5,595,375
Amortization (accretion) of note discounts, net	(12,487)		(12,487)
Gain on sale of stock in subsidiary			(2,292,800)
Non-cash (gain) loss from equity investment	96,367	165,727	656,440
Noncontrolling interest	(193,099)	(872,880)	(17,664,075)
Gain on renegotiation of accrued severance			(726,500)
Changes in operating assets and liabilities:
Receivables			(62,815)
Other receivables	(477,770)	(728,806)	(1,346,480)
Prepaid expenses	5,186	27,944	(236,388)
Other current assets	18,472	(68,950)	(96,361)
Deposits		60,105	(36,795)
Accounts payable	81,554	303,854	130,909
Accrued expenses	(91,058)	187,902	(9,361)
Accrued severance and other liabilities	47,798	20,775	1,006,412
NET CASH USED IN OPERATING ACTIVITIES OF CONTINUING OPERATIONS	(5,993,049)	(3,168,363)	(58,874,761)
CASH FLOWS FROM INVESTING ACTIVITIES OF CONTINUING OPERATIONS:
Purchase of marketable securities - US Treasury Bills			(18,575,915)
Purchase of property and equipment	(9,674)		(3,565,599)
Purchase of MASA Energy, LLC			(250,000)
Minority equity investment			(2,000,000)
Cash paid for interest in Insert			(10,150,000)
Cash obtained from interest in Insert			10,529,594
Proceeds from sale of marketable securities - US Treasury Bills			18,888,265
Proceeds from sale of investments	1,130,307		2,400,220
Proceeds from sale of subsidiaries	254,275		359,375
Proceeds from sale of fixed assets			142,375
Payment for patents			(303,440)
Restricted cash			50,773
Cash transferred in sale of subsidiary	(1,700,398)		(1,700,398)
NET CASH USED IN INVESTING ACTIVITIES OF CONTINUING OPERATIONS	(579,765)		(4,174,750)
CASH FLOWS FROM FINANCING ACTIVITIES OF CONTINUING OPERATIONS:
Proceeds from issuance of Calando debt			2,516,467
Proceeds from sale of stock in subsidiary	1,719,158		20,894,326
Proceeds from issuance of common stock and warrants, net	57,163	12,071,255	90,844,554
NET CASH PROVIDED BY FINANCING ACTIVITIES OF CONTINUING OPERATIONS	1,776,321	12,071,255	114,255,347
Cash flows from discontinued operations:
Operating cash flows	2,265,639	(2,017,982)	(46,003,153)
Investing cash flows		430,000	790,625
Financing cash flows		(351,689)	(1,677,000)
Net cash provided by (used in) discontinued operations:	2,265,639	(1,939,671)	(46,889,528)
NET INCREASE (DECREASE) IN CASH	(2,530,854)	6,963,221	4,316,308
CASH AT BEGINNING OF PERIOD	6,847,162	2,020,224
CASH AT END OF PERIOD	4,316,308	8,983,445	4,316,308
Supplementary disclosures:
Interest paid	105,000	$ 26,406	230,419
Taxes paid	$ 742,500		$ 742,500

Consolidated Statements Of Cash Flows (Parenthetical) - USD ($)	Nov. 30, 2010	Sep. 30, 2010	Mar. 31, 2010	Feb. 28, 2010	Sep. 30, 2009	Sep. 28, 2009	Sep. 22, 2009	Jun. 25, 2009	Jun. 11, 2009	Aug. 08, 2008	Apr. 29, 2008	Apr. 23, 2008	Apr. 20, 2007	Mar. 31, 2006	Mar. 23, 2005
Common stock, shares issued		71,720,137
Common stock value		$ 71,735
Warrants exercised			247,880
Stock issued against warrants			128,707
Insert Therapeutics, Inc [Member]
Purchase of common shares															7,375,000
Common stock, shares issued															502,260
Common stock value															$ 2,000,000
Calando Pharmaceuticals, Inc [Member]
Purchase of common shares	2,850,000			200,000										964,000
Common stock, shares issued	1,140,000			80,000										208,382
Common stock value	$ 706,800													$ 1,077,333
Value of common stock purchased														1,928,000
Stock purchased by cash														$ 850,667
Warrants issued	240,000			24,000
Warrants purchased	600,000			60,000
Common stock exercise value				$ 0.50
Unidym, Inc [Member]
Purchase of common shares												200,000
Common stock, shares issued						642,273						70,547
Common stock value						$ 398,209
Value of common stock purchased												$ 200,000
MASA Energy LLC [Member]
Common stock, shares issued											105,049
Common stock value											$ 310,000
Value of common stock purchased											560,000
Stock purchased by cash											$ 250,000
Nanoconduction, Inc [Member]
Common stock, shares issued										114,115
Common stock value										$ 250,000
Series E Preferred Stock [Member] \| Carbon Nanotechnologies, Inc [Member]
Common stock, shares issued													1,431,222
Common stock value													$ 5,400,000
Series A Preferred Stock [Member] \| Calando Pharmaceuticals, Inc [Member]
Purchase of common shares		1,562.5
Warrants issued		3,906,250
Common stock exercise value		$ 0.50
Series A Preferred Stock [Member] \| Unidym, Inc [Member]
Purchase of common shares						5,574
Common stock, shares issued							91,495		1,324,625
Common stock value							$ 46,662		$ 688,802
Series C Preferred Stock [Member] \| Unidym, Inc [Member]
Purchase of common shares						636,699
Common stock, shares issued	153,176							1,944,444
Common stock value	$ 47,485							$ 972,222
Series C-1 Preferred Stock [Member] \| Unidym, Inc [Member]
Common stock, shares issued					277,778
Common stock value					$ 186,111

Organization And Basis Of Presentation

9 Months Ended

Jun. 30, 2011

Organization And Basis Of Presentation

Organization And Basis Of Presentation

NOTE 1. ORGANIZATION AND BASIS OF PRESENTATION

Nature of Business

Arrowhead Research Corporation is a nanomedicine company developing innovative therapies at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through ownership in subsidiaries that are selected based on synergies in their technology, and clinical and business strategies. By focusing on specific related applications of nanomedicine, Arrowhead and its subsidiaries leverage shared expertise and resources to develop pioneering therapeutic platforms for large unmet medical needs. We are currently focused on the preclinical and clinical development of therapeutics for the treatment of cancer and obesity, as well as the regeneration of wounded or diseased tissue.

Arrowhead's portfolio includes two majority owned subsidiaries, Calando, a leader in delivering small RNAs for gene silencing, and Ablaris, an anti-obesity therapeutics company, and minority investments in Nanotope, a regenerative medicine company and Leonardo, a multistage drug delivery company.

Liquidity

Arrowhead has historically financed its operations through the sale of securities of Arrowhead and its Subsidiaries. Development activities at our Subsidiaries has required significant capital investment since the Company's inception and we expect our current portfolio companies to continue to require cash investment in fiscal 2011 and beyond to continue development.

At June 30, 2011, the Company had approximately $4.3 million in cash to fund operations. During the first nine months of fiscal 2011, the Company's cash position decreased by $2.5 million, primarily due to operational spending at Arrowhead and Calando. In January 2011, Arrowhead sold its ownership interest in Unidym; therefore the cash burn associated with Unidym ceased in January 2011. As a result of the sale of Unidym, the Company received $2.5 million in stock of the acquirer, Wisepower Co. Ltd. ("Wisepower") and a $2.5 million convertible bond from Wisepower, of which approximately $200,000 is owed to a third party, who was a minority investor in Unidym. As of June 30, 2011, the Company sold approximately 40% of the stock for approximately $1.1 million. As of June 30, 2011, the remaining shares, net of amount owed to third parties, had a market value of approximately $1.2 million. The terms of the agreements with Wisepower allow for the sale of the stock over time, subject to certain trading limitations ending in October 2011. Arrowhead intends to dispose of its remaining shares as allowed, subject to market conditions. The convertible bond with a face value of $2.5 million, is convertible into Wisepower common stock beginning on January 17, 2012 at a price of $2.00 per share, and at that point would represent an additional source of liquidity for the company, subject to the then-current market value of the common stock. Finally, the Company has the ability to exercise the redemption feature of certain warrants outstanding which could yield proceeds of approximately $4.0 million. Based upon the Company's cash on hand, other sources of liquidity, as described above, and based upon the Company's operating plan, the Company's management anticipates that the Company will be able to satisfy the cash requirements of its operations through at least the next twelve months. The Company anticipates that further equity financings, and/or asset sales and license agreements will be necessary to continue to fund operations in the future.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring accruals, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year. The September 30, 2010 balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. This financial information should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended September 30, 2010.

The consolidated financial statements of the Company include the accounts of Arrowhead and its wholly-owned and majority-owned Subsidiaries. Prior to April 2008, Arrowhead's Subsidiaries included Insert Therapeutics, Inc. ("Insert"), which was merged with Calando in April 2008. The merged entity is majority-owned by Arrowhead and continues to operate under the name of Calando. On January 17, 2011, Arrowhead sold its interests in Unidym to Wisepower, and on December 23, 2009, Tego completed a sale of its assets to Luna Innovations, Inc. Unidym and Tego results are included in the Income (Loss) from Discontinued Operations. Income (Loss) from Discontinued Operations also includes Aonex Technologies, Inc. ("Aonex"), sold in May 2008 and Nanotechnica, Inc. ("Nanotechnica"), dissolved in June 2005. All significant intercompany accounts and transactions are eliminated in consolidation, and noncontrolling interests are accounted for in the Company's financial statements. Certain reclassifications have been made to prior period financial statements to conform to the current period presentation.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Actual results could differ from those estimates.

Recently Issued Accounting Standards

In June 2010, the FASB issued ASU No. 2010-17, Revenue Recognition—Milestone Method (Topic 605): Milestone Method of Revenue Recognition. This ASU codifies the consensus reached in EITF Issue No. 08-9, "Milestone Method of Revenue Recognition." The amendments to the Codification provide guidance on defining a milestone and determining when it may be appropriate to apply the milestone method of revenue recognition for research or development transactions. Consideration that is contingent on achievement of a milestone in its entirety may be recognized as revenue in the period in which the milestone is achieved only if the milestone is judged to meet certain criteria to be considered substantive. Milestones should be considered substantive in their entirety and may not be bifurcated. An arrangement may contain both substantive and nonsubstantive milestones, and each milestone should be evaluated individually to determine if it is substantive. This guidance was adopted effective October 1, 2010. The adoption of this guidance did not have a material impact on our consolidated financial statements.

In January 2010, the FASB issued Accounting Standards Update ASU No. 2010-06, "Fair Value Measurements and Disclosures (Topic 820) – Improving Disclosures about Fair Value Measurements". This guidance requires new disclosures related to recurring and nonrecurring fair value measurements. The guidance requires disclosure of transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy, including the reasons and the timing of the transfers and information on purchases, sales, issuance, and settlements on a gross basis in the reconciliation of the assets and liabilities measured under Level 3 of the fair value measurement hierarchy. The adoption of this guidance is effective for interim and annual reporting periods beginning after December 15, 2009. We have adopted this guidance in the financial statements presented herein, which did not have a material impact on our consolidated financial position or results of operations.

In October 2009, the FASB issued ASU 2009-13, which amends ASC Topic 605, Revenue Recognition. This new accounting guidance relates to the revenue recognition of multiple element arrangements. The new guidance states that, if vendor specific objective evidence or third party evidence for deliverables in an arrangement cannot be determined, companies will be required to develop a best estimate of the selling price for separate deliverables and allocate arrangement consideration using the relative selling price method. We adopted this guidance as of January 1, 2010 on a prospective basis. The adoption of this guidance did not have a material impact on our consolidated financial statements.

In October 2009, the FASB issued authoritative guidance on multiple-deliverable revenue arrangements, ASC 605-25. This guidance amends the existing criteria for separating consideration received in multiple-deliverable arrangements and requires that arrangement consideration be allocated at the inception of the arrangement to all deliverables based on their relative selling price. The guidance establishes a hierarchy for determining the selling price of a deliverable which is based on vendor-specific objective evidence, third-party evidence, or management estimates. Expanded disclosures related to multiple-deliverable revenue arrangements are also required. This guidance is effective for the Company beginning fiscal year 2011. We have adopted this guidance in the financial statements presented herein, which did not impact our consolidated financial position or results of operations.

On July 1, 2009, the FASB issued the FASB Accounting Standards Codification (the Codification). The Codification became the single source of authoritative non-governmental U.S. generally accepted accounting principles ("GAAP"), superseding existing FASB, American Institute of Certified Public Accountants ("AICPA"), Emerging Issues Task Force ("EITF") and related literature. The Codification eliminates the previous U.S. GAAP hierarchy and establishes one level of authoritative GAAP. All other literature is considered non-authoritative. The Codification was effective for interim and annual periods ending after September 15, 2009. The Company adopted the Codification for the year ended September 30, 2009. This guidance did not change GAAP; therefore it did not have an impact on our consolidated financial statements. References within this note and throughout our financial statements to authoritative guidance issued by the FASB are in reference to the codification.

In June 2009, the FASB issued guidance codified as ASC 470-20, regarding accounting for own-share lending arrangements in contemplation of convertible debt issuance, which changes the accounting for equity share lending arrangements on an entity's own shares when executed in contemplation of a convertible debt offering. This guidance requires the share lending arrangement to be measured at fair value and recognized as an issuance cost. These issuance costs should then be amortized as interest expense over the life of the financing arrangement. Shares loaned under these arrangements should be excluded from computation of earnings per share. This guidance is effective for fiscal years beginning after December 15, 2009 and requires retrospective application for all arrangements outstanding as of the beginning of the fiscal year. We have adopted this guidance in the financial statements presented herein, which did not impact our consolidated financial position or results of operations.

In June 2009, the FASB issued amendments to the accounting rules for variable interest entities (VIEs) and for transfers of financial assets, codified as ASC 860-10. The new guidance for VIEs eliminates the quantitative approach previously required for determining the primary beneficiary of a variable interest entity and requires ongoing qualitative reassessments of whether an enterprise is the primary beneficiary. In addition, qualifying special purpose entities ("QSPEs") are no longer exempt from consolidation under the amended guidance. The amendments also limit the circumstances in which a financial asset, or a portion of a financial asset, should be derecognized when the transferor has not transferred the entire original financial asset to an entity that is not consolidated with the transferor in the financial statements being presented, and/or when the transferor has continuing involvement with the transferred financial asset. This guidance is effective as of the beginning of a reporting entity's first annual reporting period that begins after November 15, 2009 and for interim periods within the first annual reporting period. This guidance became effective on October 1, 2010. We have adopted this guidance in the financial statements presented herein, which did not impact our consolidated financial position or results of operations.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Name Statement of Position (SOP)
-Publisher AICPA
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Name FASB Interpretation (FIN)
-Publisher FASB
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6359553&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6921930&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6970148&loc=SL6228881-111685

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Investment In Subsidiaries

9 Months Ended

Jun. 30, 2011

Investment In Subsidiaries

Investment In Subsidiaries

NOTE 2. INVESTMENT IN SUBSIDIARIES

Calando Pharmaceuticals, Inc. (formerly known as Insert Therapeutics, Inc. "Insert")

Calando is a clinical stage nanobiotechnology company at the forefront of RNAi therapeutics. Calando is developing nanoparticle therapeutics that use our patented sugar (cyclodextrin)-based polymer technologies as a drug delivery system for siRNA.

On April 17, 2008, Calando merged with and into Insert, with Insert as the surviving company. Prior to the merger, Arrowhead invested an aggregate of $23.2 million in Calando through the purchase of equity and loans. As a condition of the merger, the Preferred Stock of each of Calando and Insert was converted into common stock and the loans were converted to equity. As a result of the merger, shares of Insert common stock were issued to the stockholders of the former Calando, and Insert changed its name to Calando Pharmaceuticals, Inc.

On November 26, 2008, Calando entered into Unsecured Convertible Promissory Note Agreements ("Notes") for $2.5 million with accredited investors and Arrowhead, which invested $200,000 in the Notes offering. Arrowhead subsequently invested an additional $600,000 in the same offering. Except for one Note in the principal amount of $500,000, all Notes and accrued interest were converted into a total of 2,950 shares of Calando Series A Preferred Stock on June 23, 2009. The remaining Note is due November 26, 2013; see Note 4 for further information.

In fiscal 2010, Arrowhead issued 1,220,000 shares of its Common Stock in exchange for 3,050,000 shares of Calando common stock, with several minority stockholders of Calando. In conjunction with this exchange, Arrowhead also issued warrants to purchase 264,000 shares of Arrowhead Common Stock in exchange for warrants to purchase 660,000 shares of Calando common stock. Also in fiscal 2010, Arrowhead issued warrants to purchase up to 3,906,250 shares of its Common Stock in exchange for 1,562.5 shares of Calando Series A Preferred Stock. The Calando Series A Preferred Stock have a liquidation preference and are convertible into 3,381,303 shares of Calando common stock.

In January 2011, Arrowhead invested $9.1 million, through a cash investment of $1.0 million and the conversion of $8.1 million intercompany debt, acquiring newly issued Calando Series B and Series C preferred stock.

As of June 30, 2011, Arrowhead had advances outstanding to Calando totaling $0.4 million.

As of June 30, 2011, Arrowhead owned 79% of the outstanding shares of Calando and 73% on a fully diluted basis.

Ablaris Therapeutics, Inc.

Ablaris was formed and began operations in the first quarter of fiscal 2011 through the licensing of certain anti-obesity technology developed at the MD Anderson Cancer Center at the University of Texas. During the nine months ended June 30, 2011, Ablaris raised $2.9 million in cash, of which $1.3 million was invested by Arrowhead and $1.6 million was invested by outside investors, through the issuance of Series A Preferred stock.

As of June 30, 2011, Arrowhead owned 64% of the outstanding shares of Ablaris and 64% on a fully diluted basis.

Nanotope, Inc.

Nanotope is developing advanced nanomaterials for the treatment of spinal cord injuries, cartilage regeneration and wound healing. As of June 30, 2011, Arrowhead owned 23% of the outstanding shares of Nanotope, 19% on a fully diluted basis. Arrowhead accounts for its investment in Nanotope using the equity method of accounting. As of June 30, 2011, Nanotope had indebtedness to Arrowhead in the amount of $1.1 million, which Arrowhead has included in other receivables. It is expected that this indebtedness will be repaid or converted to equity.

Summarized financial information for Nanotope, Inc. is as follows:


	June 30, 2011			September 30, 2010
Current assets	$	185,000		$	16,000
Non-current assets		100,000			130,000
Liabilities		1,143,000			585,000
Equity		(858,000	)		(439,000	)


	For the three months ended June 30, 2011			For the three months ended June 30, 2010			For the nine months ended June 30, 2011			For the nine months ended June 30, 2010
Revenue	$	3,000		$	—		$	515,000		$	9,000
Operating expenses		283,000			300,000			896,0000			758,000
Net loss		(306,000	)		(300,000	)		(419,000	)		(748,000	)


	For the nine months ended June 30, 2011			For the nine months ended June 30, 2010
Cash flows used in operating activities	$	(427,000	)	$	(331,000	)
Cash flows used in investing activities		(28,000	)		(7,000	)
Cash flows provided by financing activities		628,000			—

Leonardo Biosystems, Inc.

Leonardo is developing a drug-delivery platform technology based on novel methods of designing spheroid porous silicon microparticles that selectively accumulate in tumor vasculature. Arrowhead accounts for its investment in Leonardo using the cost method of accounting. As of June 30, 2011, Leonardo had indebtedness to Arrowhead in the amount of $255,000, included in other receivables, which is expected to be repaid or converted to equity. As of June 30, 2011, Arrowhead's ownership interest in Leonardo was 5%.

- Definition

The entire disclosure for equity investment, or group of investments, for which combined disclosure is appropriate, including: (a) the name of each investee and percentage of ownership of common stock, (b) accounting policies for investments in common stock, (c) difference between the amount at which the investment is carried and the amount of underlying equity in net assets and the accounting treatment of the difference, (d) the total fair value of each identified investment for which a market value is available, (e) summarized information as to assets, liabilities, and results of operations of the investees (for investments in unconsolidated subsidiaries, common stock of joint ventures, or other investments using the equity method), and (f) material effects of possible conversions, exercises, or contingent issuances of the investee. Other disclosures include (a) the names of any investee in which the investor owns 20 percent or more of the voting stock and investment is not accounted for using the equity method, and the reasons why not, and (b) the names of any investee in which the investor owns less than 20 percent of the voting stock and the investment is accounted for using the equity method, and the reasons why it is.

+ References + Details

Discontinued Operations

9 Months Ended

Jun. 30, 2011

Discontinued Operations

Discontinued Operations

NOTE 3. DISCONTINUED OPERATIONS

Unidym, Inc.

Founded by Arrowhead in 2005, Unidym is developing electronic applications of carbon nanotubes. In line with the Company's strategy to focus on nanomedicine, Arrowhead sold its ownership interest in Unidym to Wisepower in January 2011. The consideration included $5.0 million in Wisepower stock and bonds, a percentage of certain revenue streams, as well as contingent payments up to $140 million based on revenue milestones over a ten-year period.

In conjunction with the disposition of Unidym, the gain on the sale and the results of historical operations are recorded as discontinued operations in the Company's Statements of Operations. Additionally, the cash flows from Unidym are reflected separately as cash flows from discontinued operations. Potential future cash flows as discussed above will be reflected as a part of cash flows from discontinued operations in the Company's Consolidated Statements of Cash Flows.

Tego Biosciences, Inc.

On April 20, 2007, Tego, a wholly-owned subsidiary of Arrowhead, acquired the assets of C Sixty, Inc., a Texas-based company developing protective products based on the anti-oxidant properties of fullerenes.

On December 23, 2009, Tego completed the sale of all of its non-cash intellectual property assets to Luna Innovations, Inc.

The consideration included an upfront purchase price of $350,000 and reimbursements of patent and license expenses of $80,000 as well as contingent payments based on milestones and royalties for each fullerene product developed by Luna and covered by Tego intellectual property.

Due to the sale of substantially all of Tego's assets, the operations of Tego ceased and the gain on the sale and the results of historical operations are recorded as discontinued operation in the Company's Statements of Operations. Additionally, the cash flows from Tego are reflected separately as cash flows from discontinued operations. Potential future cash flows associated with the Luna APA, as discussed above, will be reflected as a part of cash flows from discontinued operations in the Company's Consolidated Statements of Cash Flows.

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 43-48
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6390789&loc=d3e2443-110228

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

+ Details

Notes Payable

9 Months Ended

Jun. 30, 2011

Notes Payable

Notes Payable

NOTE 4. NOTES PAYABLE

On November 26, 2008, Calando entered into Unsecured Convertible Promissory Note Agreements ("Notes") for $2.5 million with accredited investors and Arrowhead, which invested $200,000 in the Notes offering. Arrowhead subsequently invested an additional $600,000 in the same offering. Except for one Note in the principal amount of $500,000, all Notes and accrued interest were converted into a total of 2,950 shares of Calando Series A Preferred Stock on June 23, 2009. The remaining Note had a 10% interest rate, matured on November 26, 2010, and was renegotiated and extended until November 2013. The terms of the new note include a 10% interest rate and require two times principal payment upon certain events as defined in the note and at maturity.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Stockholders' Equity

9 Months Ended

Jun. 30, 2011

Stockholders' Equity

Stockholders' Equity

NOTE 5. STOCKHOLDERS' EQUITY

At June 30, 2011, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001, and 5,000,000 shares of Preferred Stock, par value $0.001.

At June 30, 2011, 71,833,693 shares of Common Stock were outstanding. At June 30, 2011, 1,532,000 shares and 9,704,436 shares were reserved for issuance under Arrowhead's 2000 Stock Option Plan and 2004 Equity Incentive Plan, respectively.

On July 17, 2009 and August 6, 2009, the Company sold an aggregate of 9,196,642 units in a private placement transaction with institutional and accredited investors. Each unit consisted of one share of Arrowhead Common Stock and a warrant to purchase an additional share of Common Stock exercisable at $0.50 per share; the unit price was $0.30. The warrants became exercisable on January 18, 2010 and February 7, 2010, and remain exercisable until June 30, 2014. The warrants can be called for redemption by the Company as the redemption feature provided for in the warrants has been met. Gross proceeds of the offering totaled approximately $2.8 million.

On December 11, 2009, the Company sold an aggregate of 5,083,430 units in a private placement transaction with accredited investors. Each unit consisted of one share of Arrowhead Common Stock and a warrant to purchase an additional share of Common Stock exercisable at $0.509 per share. The unit price was $0.634, based upon the closing bid price on the Company's Common Stock on December 11, 2009, which was $0.509, plus $0.125 for the purchase of the warrant. The warrants became exercisable on June 12, 2010 and remain exercisable until December 11, 2014. The warrants can be called for redemption by the Company as the redemption feature provided for in the warrants has been met. Gross proceeds of the offering were approximately $3.2 million.

On June 17, 2010, the Company sold an aggregate of 6,592,989 units at a price of $1.312 per unit in a registered offering to institutional and individual investors. Each unit consisted of one share of Arrowhead Common Stock and a warrant to purchase 0.5 share of Common Stock exercisable at $1.65 per share. The warrants contain an antidilution provision which can result in an adjustment to the exercise price under certain circumstances (see Note 9 for additional information). Gross proceeds from the offering were $8.65 million before deducting placement agent commission and other offering expenses.

The following table summarizes information about warrants outstanding at June 30, 2011:


Exercise prices	Number of Warrants		Remaining Life in Years
$7.06		948,969		5.9
$2.00		3,863,999		2.1
$0.50		11,630,335		3.4
$0.51		4,610,244		3.5
$1.65		3,296,497		4.5

Total warrants outstanding		24,350,044

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph d

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7, 11A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

+ Details

Leases

9 Months Ended

Jun. 30, 2011

Leases

Leases

NOTE 6. LEASES

During the three months ended June 30, 2011, the Company's corporate headquarters lease expired, and the Company did not elect its renewal option. The company is currently leasing temporary office space and is negotiating terms of a new corporate headquarters, including lab facilities. The temporary space is expected to be utilized for several months, and the cost is approximately $6,400 per month.

Facility and equipment rent expense for the three months ended June 30, 2011 and 2010 was $36,061 and $53,669, respectively. For the nine months ended June 30, 2011 and 2010, rent expense was $140,859 and $183,798, respectively. From inception to date, rent expense was $3,624,481. Rent expense related to Unidym is included as a part of income/loss from discontinued operations.

- Definition

The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.

+ References + Details

Stock-Based Compensation

9 Months Ended

Jun. 30, 2011

Stock-Based Compensation

Stock-Based Compensation

NOTE 7. STOCK-BASED COMPENSATION

Arrowhead has two plans that provide for equity-based compensation. Under the 2000 Stock Option Plan, 1,532,000 shares of Arrowhead's Common Stock are reserved for issuance upon exercise of non-qualified stock options. No further grants can be made under the 2000 Stock Option Plan. The 2004 Equity Incentive Plan reserves 9,704,436 shares for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards by the Board of Directors to employees, consultants and others. As of June 30, 2011, there were options granted and outstanding to purchase 1,532,000 and 5,702,776 shares of Common Stock under the 2000 Stock Option Plan and the 2004 Equity Incentive Plan, respectively. During the nine months ended June 30, 2011, 120,000 options were granted under the 2004 Equity Incentive Plan.

The following tables summarize information about stock options:


	Number of Options Outstanding			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value
Balance At September 30, 2009		2,901,588		$	1.73
Granted		5,251,750			0.69
Cancelled		(23,125	)		1.11
Exercised		(6,875	)		1.11

Balance At September 30, 2010		8,123,338			1.06
Granted		120,000			0.65
Cancelled		(981,563	)		2.17
Exercised		(26,999	)		0.51

Balance At June 30, 2011		7,234,776		$	0.91		7.3 years	$	2,400

Exercisable At June 30, 2011		5,245,809		$	0.98		7.0 years	$	2,400

Stock-based compensation expense for the nine months ended June 30, 2011 and 2010 was $1,078,951 and $895,398, respectively. Stock-based compensation expense, except for the portion of stock-based compensation expense relating to Unidym, is shown as a separate line item in the Company's consolidated statements of operations. Stock-based compensation expense related to Unidym is included in income/loss from discontinued operations. There is no income tax benefit as the company is currently operating at a loss and an actual income tax benefit may not be realized. The result of the loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.

As of June 30, 2011, the pre-tax compensation expense for all unvested stock options at Arrowhead in the amount of approximately $1,313,346 will be recognized in our results of operations over a weighted average period of 2.4 years. As of June 30, 2011, the pre-tax compensation expense for all unvested stock options at Calando in the amount of approximately $81,931 will be recognized in our results of operations over a weighted average period of 1.1 years.

The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by our stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company's employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. The assumptions used to value Arrowhead stock options granted are as follows:


	Nine months Ended June 30,
	2011	2010
Dividend yield	—	—
Risk-free interest rate	2.90%	2.62% to 3.42%
Volatility	100%	100%
Expected life (in years)	6.25	5 to 6.25
Weighted average grant date fair value per share of options granted	$0.52	$0.47

The dividend yield is zero as the Company currently does not pay a dividend.

The risk-free interest rate is based on the US Treasury bond.

Volatility is estimated based on volatility average of the Company's Common Stock price.

- Definition

Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.

+ References + Details

Fair Value Measurements & Derivative Instruments

9 Months Ended

Jun. 30, 2011

Fair Value Measurements & Derivative Instruments

Fair Value Measurements & Derivative Instruments

NOTE 8. FAIR VALUE MEASUREMENTS & DERIVATIVE INSTRUMENTS

The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level 1 provides the most reliable measure of fair value, while Level 3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows:

Level 1—Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly.

Level 3—Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management's best estimate of what market participants would use in valuing the asset or liability at the measurement date.

The following table summarizes fair value measurements at June 30, 2011 for assets and liabilities measured at fair value on a recurring basis:


	Level I		Level II		Level III		Total
Cash and cash equivalents	$	4,316,308	$	—	$	—	$	4,316,308
Marketable securities	$	1,177,708	$	—	$	—	$	1,177,708
Derivative assets	$	—	$	—	$	284,625	$	284,625
Derivative liabilities	$	—	$	—	$	958,451	$	958,451

As part of the sale of Unidym in January 2011, Arrowhead received common stock in Wisepower, originally valued at $2.5 million, $100,000 of which is due to a third party. Arrowhead has the ability to sell the shares of stock in Wisepower, subject to certain limits on volume of sales over a nine-month period ending in October 2011. During the nine months ended June 30, 2011, Arrowhead sold approximately 40% of the original holdings; the remaining shares had a market value of $1.2 million at June 30, 2011. The recorded value of the stock is adjusted to fair market value based on quotations from the KOSDAQ, a Korean stock exchange, and published foreign exchange rates. Marketable securities are included as part of other current assets in the Company's consolidated balance sheet.

As part of the sale of Unidym in January 2011, Arrowhead received a bond from Wisepower in the face amount of $2.5 million. The bond is convertible to Wisepower common stock beginning on January 17, 2012 at a price of $2.00 per share. The conversion feature is subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the conversion feature on the date of issuance was estimated using an option pricing model and recorded on the Company's consolidated balance sheet as a derivative asset. The fair value of the conversion feature is estimated at the end of each reporting period and the change in the fair value of the conversion feature is recorded as a nonoperating gain/loss as change in value of derivatives in Company's consolidated statement of operations. A portion of the bond is owed to a third party, as such the company records a derivative asset for entire conversion feature and records a derivative liability for the portion related to the third party. The original fair value of the derivative relating to the third party was $26,310; the fair value at June 30, 2011 was $12,107. The gain of $14,203 is reflected in the change in value of derivatives in the Company's consolidated statement of operations.

During the nine months ended June 30, 2011, the Company recorded a loss from the change in fair value of the derivative asset of $333,875. The assumptions used in valuing the derivative asset as of June 30, 2011 were as follows:


Risk free interest rate	0.8	%
Expected life	2.6 Years
Dividend yield	none
Volatility	72	%

The following is a reconciliation of the derivative asset for the nine months ended June 30, 2011:


Value at October 1, 2010	$	—
Receipt of instruments		618,500
Decrease in value		(333,875	)
Net settlements		—

Value at June 30, 2011	$	284,625

As part of the equity financing on June 17, 2010, as described in Note 5, Arrowhead issued warrants to acquire up to 3,296,497 shares of common stock (the "Warrants") which contain anti-dilution protection. Under the certain provisions of the Warrants, if, during the term of the Warrants, the Company issues Common Stock at a price lower than the exercise price of the Warrants, the exercise price of the Warrants would be reduced to the amount equal to the issuance price of the Common Stock. Because the Warrants have this feature, the Warrants are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the Warrants on the date of issuance was estimated using an option pricing model and recorded on the Company's consolidated balance sheet as a derivative liability. The fair value of the Warrants is estimated at the end of each reporting period and the change in the fair value of the Warrants is recorded as a nonoperating gain or loss in the Company's consolidated statement of operations. During the nine months ended June 30, 2011, the Company recorded a gain from the change in fair value of the derivative liability of $1,511,139. The assumptions used in valuing the derivative liability as of June 30, 2011 were as follows:


Risk free interest rate	1.8	%
Expected life	4.5 Years
Dividend yield	none
Volatility	100	%

In conjunction with the financing of Ablaris during the three months ended March 31, 2011, Arrowhead sold exchange rights to certain investors whereby the investors have the right to exchange their shares of Ablaris for a prescribed number of Arrowhead shares based upon a predefined ratio. The exchange rights have a seven-year term. During the first year, the exchange right allows the holder to exchange one Ablaris share for 0.6 Arrowhead shares. This ratio declines to 0.4 in the second year, 0.3 in the third year and 0.2 in the fourth year. In the fifth year and beyond the exchange ratio is 0.1. Exchange rights for 675,000 Ablaris shares were sold during the nine months ended June 30, 2011, and remain outstanding at June 30, 2011. The exchange rights are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the exchange rights on the date of issuance was estimated using an option pricing model and recorded on the Company's consolidated balance sheet as a derivative liability. The fair value of the exchange rights is estimated at the end of each reporting period and the change in the fair value of the exchange rights is recorded as a nonoperating gain or loss in the Company's consolidated statement of operations. During the nine months ended June 30, 2011, the Company recorded a gain from the change in fair value of the derivative liability of $51,690. The assumptions used in valuing the derivative liability as of June 30, 2011 were as follows:


Risk free interest rate	2.5	%
Expected life	6.5 Years
Dividend yield	none
Volatility	100	%

The following is a reconciliation of the derivative liability for the nine months ended June 30, 2011:


Value at October 1, 2010	$	2,408,522
Issuance of instruments		126,960
Change in value		(1,577,032	)
Net settlements		—

Value at June 30, 2011	$	958,450

The carrying amounts of the Company's other financial instruments, which include accounts receivable and accounts payable, approximate their respective fair values due to the relatively short-term nature of these instruments.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

+ Details

Related Party Transactions

9 Months Ended

Jun. 30, 2011

Related Party Transactions

Related Party Transactions

NOTE 9. RELATED PARTY TRANSACTIONS

As a founder of Nanotope, Christopher Anazalone, Arrowhead's President and CEO, owns 1,395,900 shares of Nanotope common stock, which represents approximately 14.2% of Nanotope's outstanding voting securities. Dr. Anzalone does not hold options, warrants or any other rights to acquire securities of Nanotope. Dr. Anzalone has the right to appoint a representative to the board of directors of Nanotope. Dr. Anzalone currently serves on the Nanotope board in a seat reserved for Nanotope's CEO, and another individual holds the seat designated by Dr. Anzalone. Dr. Anzalone has served as President and Chief Executive Officer of Nanotope since its formation and continues to serve in these capacities. Dr. Anzalone has not received any compensation for his work on behalf of Nanotope since joining the Company on December 1, 2007. Dr. Anzalone has also waived his right to any unpaid compensation accrued for work done on behalf of Nanotope before he joined the Company. As part of the private placement on December 11, 2009 (see Note 5. Stockholder's Equity), Dr. Anzalone personally invested $100,000.

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph k

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 3A
-Section 04
-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Label	Element	Value
Subscription Receivable [Member]
Net loss attributable to Arrowhead	us-gaap_NetIncomeLoss
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
Noncontrolling Interest [Member]
Net loss attributable to Arrowhead	us-gaap_NetIncomeLoss
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
Additional Paid-In Capital [Member]
Net loss attributable to Arrowhead	us-gaap_NetIncomeLoss
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1,510,320
Retained Earnings [Member]
Net loss attributable to Arrowhead	us-gaap_NetIncomeLoss	(95,238)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	(95,238)
Common Stock [Member]
Net loss attributable to Arrowhead	us-gaap_NetIncomeLoss
Shares, issued	us-gaap_SharesIssued	4,680,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	$ 4,680
Issued For Cash @ $1.00 Per Unit [Member]
Stock issued during period, value, new issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	1,680,000
Issued For Cash @ $1.00 Per Unit [Member] \| Subscription Receivable [Member]
Stock issued during period, value, new issues	us-gaap_StockIssuedDuringPeriodValueNewIssues
Issued For Cash @ $1.00 Per Unit [Member] \| Noncontrolling Interest [Member]
Stock issued during period, value, new issues	us-gaap_StockIssuedDuringPeriodValueNewIssues
Issued For Cash @ $1.00 Per Unit [Member] \| Additional Paid-In Capital [Member]
Stock issued during period, value, new issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	1,678,320
Issued For Cash @ $1.00 Per Unit [Member] \| Retained Earnings [Member]
Stock issued during period, value, new issues	us-gaap_StockIssuedDuringPeriodValueNewIssues
Issued For Cash @ $1.00 Per Unit [Member] \| Common Stock [Member]
Stock issued during period, value, new issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 1,680
Stock issued during period, shares, new issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	1,680,000
Stock Issuance Cost Charged To Additional Paid In Capital [Member]
Stock issuance cost charged to additional paid-in capital	us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	$ (168,000)
Stock Issuance Cost Charged To Additional Paid In Capital [Member] \| Subscription Receivable [Member]
Stock issuance cost charged to additional paid-in capital	us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
Stock Issuance Cost Charged To Additional Paid In Capital [Member] \| Noncontrolling Interest [Member]
Stock issuance cost charged to additional paid-in capital	us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
Stock Issuance Cost Charged To Additional Paid In Capital [Member] \| Additional Paid-In Capital [Member]
Stock issuance cost charged to additional paid-in capital	us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	(168,000)
Stock Issuance Cost Charged To Additional Paid In Capital [Member] \| Retained Earnings [Member]
Stock issuance cost charged to additional paid-in capital	us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
Stock Issuance Cost Charged To Additional Paid In Capital [Member] \| Common Stock [Member]
Stock issuance cost charged to additional paid-in capital	us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
Issued For Cash @ $0.001 Per Unit [Member]
Stock issued during period, value, new issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	3,000
Issued For Cash @ $0.001 Per Unit [Member] \| Subscription Receivable [Member]
Stock issued during period, value, new issues	us-gaap_StockIssuedDuringPeriodValueNewIssues
Issued For Cash @ $0.001 Per Unit [Member] \| Noncontrolling Interest [Member]
Stock issued during period, value, new issues	us-gaap_StockIssuedDuringPeriodValueNewIssues
Issued For Cash @ $0.001 Per Unit [Member] \| Additional Paid-In Capital [Member]
Stock issued during period, value, new issues	us-gaap_StockIssuedDuringPeriodValueNewIssues
Issued For Cash @ $0.001 Per Unit [Member] \| Retained Earnings [Member]
Stock issued during period, value, new issues	us-gaap_StockIssuedDuringPeriodValueNewIssues
Issued For Cash @ $0.001 Per Unit [Member] \| Common Stock [Member]
Stock issued during period, value, new issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 3,000
Stock issued during period, shares, new issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	3,000,000